Overview

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Status:
Completed
Trial end date:
2020-03-17
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cisplatin
Gemcitabine